Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129570 · ClinicalTrials.gov registry record · Phase 1
Siliphos in Advanced Hepatocellular Carcinoma
A Phase 1 study of Advanced Hepatocellular Carcinoma, sponsored by Abby Siegel.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT01129570 is a Phase 1 study of Advanced Hepatocellular Carcinoma that has completed, run by Abby Siegel. The registered enrollment target is 3 participants, below the 87-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01129570, a Phase 1 study of Advanced Hepatocellular Carcinoma, has completed, sponsored by Abby Siegel.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States. It has not been used in patients with liver cancer previously, to our knowledge, but there have been many studies of its use in patients with hepatitis and cirrhosis. Some of these studies have shown that milk thistle may help reduce elevated liver function tests. Siliphos is a derivative of milk thistle that can be absorbed better than some other types of milk thistle. The investigators would like to perform a study to identify doses of siliphos that are safe to take in advanced liver cancer and to identify positive or negative side effects this compound may have. The investigators will be using this information in future studies to see if siliphos can be used as a therapy in patients with advanced liver cancer to reduce elevated liver function tests.
Conditions Studied
Interventions
- DRUG Silybin
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129570
The ClinicalTrials.gov registry entry for NCT01129570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Abby Siegel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Silybin is the first listed.
NCT01129570 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01129570 about?
NCT01129570 is a clinical study titled "Siliphos in Advanced Hepatocellular Carcinoma". Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States. It has not been used in...
What is the current status of trial NCT01129570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2010-02. Estimated completion is 2013-06.
What conditions does trial NCT01129570 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01129570?
The interventions under investigation include: Silybin (DRUG).
Who is sponsoring clinical trial NCT01129570?
This trial is sponsored by Abby Siegel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01129570 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.